Overview

SPC2996 in Chronic Lymphocytic Leukaemia

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether SPC2996 is effective and safe in the treatment of Chronic Lymphocytic Leukaemia (CLL)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Santaris Pharma A/S